Mina called Paxlovid’s 88% efficacy against COVID-related hospitalizations and deaths “an astonishing indicator.”
In a study of 2,085 unvaccinated adults with pre-existing medical conditions (or just older), only 8, or 0.8%, were hospitalized with COVID or died of any cause, compared with 66 or 6% of those who took placebo.
The good news is that Paxlovid seems to be behaving in real conditions.
A study without a peer review of nearly 94,000 elderly or immunocompromised patients with COVID in Hong Kong, published on May 17, found that people treated with Paxlovid had a 21% reduced risk of hospitalization.
Another unaudited study, published on 1 June, found that Paxlovid was associated with a 67% and 81% drop in hospitalizations and deaths from COVID in people aged 65 and over, respectively. (But the benefits are not seen in younger adults.)
Although the drug has only been tested in unvaccinated people, there is no reason to believe that it will not work as well in vaccinated people, Mina said.
“People who are vaccinated and get a sudden infection are like anyone who gets a viral infection,” Mina said. “The availability of a drug that will significantly reduce the replication of the virus will, by all indications, reduce hospitalization and mortality in anyone who becomes infected, regardless of their vaccination status.
Rebound infections may occur after Paxlovid
You may have heard that some people taking Paxlovid may have ‘rebound infections’ when people who complete their five-day treatment with Paxlovid test positive again about two to eight days after a negative test.
Symptoms may not always recur, but they certainly can, according to the CDC’s May 24 health council.
Previous case reports indicate that rebound infections after taking Paxlovid are mild and tend to improve or resolve within about three days; no one was heavy. The CDC said there was no evidence to suggest more treatment with Paxlovid or other available therapies.
However, rebound infections may contribute to the further spread of coronavirus, although it is not known how much. In addition, they are usually uncomfortable sending people back in isolation for the recommended additional five days plus 10 days of wearing a mask after the onset of rebound symptoms.
There is still much to learn why rebound infections occur, but Mina speculates that treatment with Paxlovid is not long enough to completely wipe the virus out of people’s systems.
“The drug can serve as a crutch during your actual infection, so when you stop taking the drug, your immune system is surprised, as if it’s a new infection everywhere,” Mina said. “If we just leave the medicine for a few more days, it can actually give the body enough time to kill the whole virus.”
Dr Albert Co., a professor of public health at Raj and Indra Nui at the Yale School of Public Health, told BuzzFeed News that a reservoir of virus somewhere in the body could remain untouched by Paxlovid and cause a resurgence of symptoms and / or or positive test results days after the end of treatment. This theory may be very likely in people who naturally have a higher viral load as a start.
Mina said health professionals are likely to consider extending the duration of Paxlovid treatment to 8 or 10 days.
The CDC said that “a brief return of symptoms may be part of the natural history” of coronavirus infection in some people, regardless of treatment with Paxlovid.
Omicron may also be to blame, Mina said. Omicron is more infectious and immune-avoiding than Delta, so it may be harder for your immune system to work with Paxlovid to get rid of COVID.
People also experience symptoms of Omicron earlier than previous options, Mina said, which means they also start treatment with Paxlovid earlier in their infection. So there is a chance that we are not giving our immune system enough time to develop a stable response to treatment.
The CDC, as well as Mina and Co., still recommend Paxlovid for non-hospitalized people at high risk for severe COVID.
How does Paxlovid compare to other COVID treatments?
There are a number of treatments for COVID, but whether one is better than the other depends on the patient’s medical needs and medical history, the availability of treatments, and the options available in a given region.
What is clear, however, is that Paxlovid has become the therapy of choice for many people.
The COVID Guidelines for the Treatment of National Institutes of Health state that Paxlovid is the preferred treatment for outpatients. The next is remdesivir (brand name Veklury), which is administered intravenously and has been shown to be 87% effective against hospitalization and death in COVID among non-hospitalized patients at high risk of severe disease. Remdesivir can also be used in hospitalized patients.
Another treatment is bebtelovib, a new monoclonal antibody that can be given to non-hospitalized patients if Paxlovid or remdesivir are not available or are not safe for the patient. There are no data on the efficacy of bebtelovib yet, but the NIH said it was “active” against all Omicron sub-variants in the laboratory.
Although you could also take Lagevrio, the other new antiviral pill, studies show that it is only about 30% effective against hospitalization and death associated with COVID, so it should be used as a last resort.
How to get Paxlovid
The Biden administration launched the March 8 Treatment Initiative, which allows people to be tested for COVID at a pharmacy-based clinic, government health center or long-term care facility and receive antiviral drugs such as Paxlovid immediately if the test is positive. .
People can only receive Lagevrio and Paxlovid through the clinics participating in the initiative, which are free, whether you have insurance or not.
Here you can find places near you that are part of the Test to Treat initiative.
You can also visit your doctor (if you have one) who may prescribe Paxlovid, which you can get at your local pharmacy.
If you get a quick test for COVID at home and it comes out positive, you can get a free telemedicine visit through eMed, Mina said, during which a medical professional can prescribe treatment. (But first you need to buy a quick test from eMed – the rest is free.)
Paxlovid’s recent deliveries have not been able to meet US demand, but Pfizer employees have increased production in recent weeks. The initial shortage prevented many doctors from prescribing the drug, Mina said, because there was a lack of information about its use that came with it. “It just led to this massive misunderstanding of this really powerful drug for months,” he said.
The number of prescriptions for Paxlovid increased from about 64,000 each week in late April to about 184,000 a week until the end of May, a health and human services spokesman told BuzzFeed News by email.
About 300 Test to Treat sites have also been added since early May, with a total of about 2,600 expected to grow, the spokesman said.
Can Paxlovid reduce the likelihood of developing prolonged COVID?
Although no data has been collected on whether Palovid can reduce your chances of developing long-term COVID, Mina and Co. agree that we should expect that it can and will do so.
“We need to anticipate that early aggressive treatment to crush the virus load and destroy the virus before it can really overwhelm you must absolutely reduce the long-term symptoms of COVID,” Mina said. “The mere fact of keeping the viral load at a very low number should in itself lead to a better result in terms of reduced likelihood of prolonged COVID.
Ko admits that we still do not understand the mechanism by which some people develop long-term COVID, but knowing the links between the condition and the viral load, “very plausible” Paxlovid can help on this front.
Does Paxlovid work against different variants of COVID?
The clinical trial that determined the effectiveness of Paxlovid was conducted between July and early December, before the more infectious version of Omicron dominated the pandemic in the United States. This means that what we know about Paxlovid’s ability to fight viruses is based on infections with the non-existent Delta variant.
But the fact is that all options are and will be susceptible to the drug, Mina said. This is because it targets a different part of the coronavirus, which, at least as far as Omicron is concerned, is not affected by mutations.
“It’s so easy to catch the noise and hear all the negative things, but at the end of the day the results of the experiments were not wrong,” Mina said. “People are still saving their lives from Paxlovid.”
However, this does not mean that future options cannot develop drug resistance, both Mina and Co. said, although the CDC noted that there was no evidence that this was happening.
Add Comment